To Compare the efficacy of Full body steaming and Safoof Mohazil and Arq Zeera in patients with Obesity

Phase 2

Not yet recruiting

Conditions: Obesity, unspecified,

Registration Number: CTRI/2023/07/054770

Lead Sponsor: Central Council for Research in Unani Medicine New Delhi

Brief Summary: Obesity is a chronic lifestyle disease. Despite all modern advances in medicine an effective drug treatment of obesity has not been found yet. Unani physicians have categorized *Saman-e-Mufrat* as a *balghami* (phlegmatic) disease wherein the *Hararat e gharizya* (Innate heat) is decreased. Unani physicians have recommended *Tabkheer* (steam bath) which is a regimen employed to increase *Hararat e gharizya* (Innate heat).Also many drugs have been suggested by unani physicians as a treatment for obesity . Among such medicines *Safoof* *Mohazil* and *Arq Zeera* are considered to be known anti-obesity drugs which have been proved by many preclinical and clinical studies. However a research to explain the underlying mechanism of action and molecular pathways of both the therapy(*Tabkheer*) as well as anti-obesity unani drugs remains obscure. Therefore, in this pilot study, an attempt will be made to elucidate and compare the molecular mechanism of action of *Tabkheer*(Steam Bath)with Unani drugs *Safoof Mohazil and Arq zeera* for the treatment of obesity. Also this trial is planned to evaluate the efficacy of *Tabkheer* with classical anti-obesity Unani drugs viz. *Safoof* *Mohazil* & *Arq zeera* in *Saman-e-Mufrat* (Obesity).

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 15

Inclusion Criteria

1)Subjects with BMI>30 2)Waist circumference >102 cm in men>88cm in women 3)Patients who are ready of sign the informed consent ,follow the protocol and willing to participate in clinical study voluntarily.

Exclusion Criteria

1)Non-Cooperative patient 2)Patient below 20years and above 60years.
3)BMI<30 4)Patient who fail to give written consent.
5)Pregnant and lactating mothers.
6)Patients with local wounds and infections.
7)Unstable and mentally retarded patients.
8)Patients with portal hypertension, bleeding disorders, DM.
9)Hypothyroidism, 10)Hormonal imbalance, 11)Cardiovascular diseases, 12)Hemiplegia associated with 13)Severe hypertension, 14)Very obese patients having BMI more than 45.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1)Height & weight measurement	90 days
2)Circumferences of fatty parts (chest, abdomen, hip, mid arm, forearm, & mid-thigh before and after treatment.	90 days
3)Walking time the time taken to climb fixed number of stairs in seconds was taken as walking time.	90 days

Secondary Outcome Measures

Name	Time	Method
1)Decrease in Weight reduction	2)Decrease in chest circumference

Trial Locations

Locations (1): Regional Research Institute of Unani Medicine
🇮🇳
JAMMU, & KASHMIR, India
Regional Research Institute of Unani Medicine
🇮🇳JAMMU, & KASHMIR, India
Dr Arjumand Shah
Principal investigator
7006180746
dr.arjumandshah111@gmail.com